AbbVie (NYSE:ABBV) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

AbbVie (NYSE:ABBV) released its quarterly earnings results on Friday. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.60 by $0.05, FiscalAI reports. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.During the same period in the prior year, the firm posted $2.97 earnings per share. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie updated its Q3 2026 guidance to 3.840-3.880 EPS.

Here are the key takeaways from AbbVie’s conference call:

• Strong second-quarter execution lifted revenue 10.2% to nearly $17 billion and adjusted EPS to $3.65, beating expectations. AbbVie raised full-year revenue guidance by $300 million to approximately $67.6 billion and increased adjusted EPS guidance to $13.87–$14.07.
• Immunology and neuroscience remained key growth engines, led by SKYRIZI sales of $5.5 billion, up 24%, and RINVOQ sales above $2.5 billion, up 23.7%; neuroscience revenue grew about 20%. Management expects further SKYRIZI momentum from a potential U.S. approval of subcutaneous Crohn’s induction dosing later this year.
• AbbVie highlighted multiple pipeline and business-development catalysts, including the planned Apogee acquisition, European approvals for RINVOQ in vitiligo and alopecia areata, expected U.S. approval decisions for tavapadone, and progress across oncology ADCs and immunology combinations.
• The Apogee transaction is expected to close in the third quarter and will dilute 2026 EPS by an estimated $0.14, while increasing R&D spending and interest expense. AbbVie plans to use interim financing and issue long-term debt, targeting a return to two-times net leverage within two to three years.
• Oncology revenue declined 2.4% operationally, primarily due to expected IMBRUVICA pressure from IRA pricing and competition, while aesthetics revenue fell 0.9% as JUVÉDERM sales declined 6.6%. HUMIRA sales also fell 36.1% because of biosimilar competition.

AbbVie Stock Performance

Shares of NYSE ABBV traded down $6.08 during trading hours on Friday, hitting $251.33. 7,251,186 shares of the stock were exchanged, compared to its average volume of 7,040,380. The company has a market cap of $444.05 billion, a PE ratio of 123.81, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. The company’s fifty day simple moving average is $238.39 and its two-hundred day simple moving average is $223.86. AbbVie has a 1-year low of $187.62 and a 1-year high of $267.47.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is 340.89%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABBV. Guggenheim boosted their target price on shares of AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. BMO Capital Markets raised their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Citigroup lifted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Piper Sandler reissued an “overweight” rating and issued a $298.00 price objective on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Bank of America increased their target price on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $269.29.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Pinnacle Financial Partners Inc. lifted its stake in shares of AbbVie by 5.6% in the third quarter. Pinnacle Financial Partners Inc. now owns 181,236 shares of the company’s stock worth $41,963,000 after acquiring an additional 9,680 shares during the period. Brighton Jones LLC boosted its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Schnieders Capital Management LLC. boosted its position in AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the last quarter. Finally, Navera Investment Management Ltd. raised its position in shares of AbbVie by 139.0% in the 4th quarter. Navera Investment Management Ltd. now owns 1,195 shares of the company’s stock worth $273,000 after acquiring an additional 695 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.